Company Profile
Digitalis Ventures is a venture capital firm founded in 2016 and based in New York City. It invests in early-stage companies addressing critical unmet needs in human and animal health, across biotechnology, health technologies, diagnostics, and animal health.
The firm applies a multidisciplinary, research-driven approach—melding technical, financial, and domain expertise—and works closely with entrepreneurs, scientists, and institutions to build and scale impactful ventures. It is part of the broader Digitalis Group, alongside Digitalis Research and Digitalis Commons.
Digitalis typically invests in Seed to Series A/B rounds, leading and co‑leading funding, and closed its fourth fund in October 2022 with $300 million in commitments. Its portfolio includes companies such as Gallant Therapeutics, Galatea Bio, Aviceda Therapeutics, Nuvig Therapeutics, Terray Therapeutics, and Good Therapeutics, with exits like Scout Bio and PetMedix, demonstrating its commitment to transforming health innovation.
News & Signals (0)
No linked news activity found for this company.